Article

Mitoxantrone Hydrochloride Targets APP and LRRK2 to Improve Neurodegeneration in Parkinson’s Models

2025-10-07

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Parkinson’s disease (PD) is the second common neurodegenerative disorder, driven by the loss of dopaminergic neurons and pathological α-synuclein protein accumulation. Currently, there is no disease-modifying therapy that can halt PD progression. Our previous study uncovered a critical pathogenic feed-forward loop between amyloid precursor protein (APP) and leucine-rich repe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ea197309-f307-5465-b345-903d6eb8ef71
DOI: 10.1101/2025.10.06.680832

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mitoxantrone Hydrochloride Targets APP and LRRK2 to Improve Neurodegeneration in Parkinson’s ModelsDOI 10.1101/2025.10.06.680832Read

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s DiseasesSemantic proximity Read

Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.Semantic proximity Read

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read

Leucine‐rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule‐associated protein 1B to ameliorate lysosomal dysfunction and parkinsonismSemantic proximity Read

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read

Recent advances in targeting LRRK2 for Parkinson's disease treatment.Semantic proximity Read

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read

Role of LRRK2 in physiological activities, diseases, and therapy.Semantic proximity Read